STOCK TITAN

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
ImmunityBio, Inc. (NASDAQ: IBRX) announces positive overall survival results in the QUILT 3.055 trial for non-small cell lung cancer patients who did not respond to checkpoint inhibitors. The study showed a nearly double median overall survival compared to standard chemotherapy. ANKTIVA, an immune cell enhancer, displayed efficacy in PD-L1 negative and positive patients, activating natural killer cells and memory T cells. A meeting with the FDA is scheduled to discuss registration for ANKTIVA in combination with checkpoint inhibitors. The company received a $100 million non-dilutive cash infusion, bringing cash-on-hand to $240 million for the launch of ANKTIVA in bladder cancer. ImmunityBio plans to discuss registration plans and clinical trial pipeline during a conference call.
ImmunityBio, Inc. (NASDAQ: IBRX) annuncia risultati positivi per la sopravvivenza complessiva nello studio QUILT 3.055 per pazienti con carcinoma polmonare non a piccole cellule che non hanno risposto agli inibitori di checkpoint. Lo studio ha mostrato un raddoppio quasi della sopravvivenza mediana complessiva rispetto alla chemioterapia standard. ANKTIVA, un potenziatore delle cellule immunitarie, ha dimostrato efficacia in pazienti negativi e positivi al PD-L1, attivando le cellule killer naturali e le cellule T della memoria. È previsto un incontro con la FDA per discutere la registrazione di ANKTIVA in combinazione con gli inibitori di checkpoint. La compagnia ha ricevuto un'iniezione di contante non diluitiva di 100 milioni di dollari, portando il disponibile a 240 milioni di dollari per il lancio di ANKTIVA nel cancro alla vescica. ImmunityBio prevede di discutere i piani di registrazione e la pipeline degli studi clinici durante una teleconferenza.
ImmunityBio, Inc. (NASDAQ: IBRX) anuncia resultados positivos en la supervivencia global en el ensayo QUILT 3.055 para pacientes con cáncer de pulmón de células no pequeñas que no respondieron a los inhibidores de puntos de control. El estudio mostró una supervivencia media global casi el doble en comparación con la quimioterapia estándar. ANKTIVA, un potenciador de células inmunes, demostró eficacia en pacientes negativos y positivos para PD-L1, activando células asesinas naturales y células T de memoria. Se ha programado una reunión con la FDA para discutir el registro de ANKTIVA en combinación con inhibidores de puntos de control. La empresa recibió una infusión de efectivo no dilutiva de 100 millones de dólares, aumentando el efectivo disponible a 240 millones de dólares para el lanzamiento de ANKTIVA en cáncer de vejiga. ImmunityBio planea discutir los planes de registro y el pipeline de ensayos clínicos en una llamada de conferencia.
ImmunityBio, Inc. (NASDAQ: IBRX)은 QUILT 3.055 임상 시험에서 체크포인트 억제제에 반응하지 않은 비소세포 폐암 환자의 전반적인 생존 결과에 대해 긍정적인 결과를 발표했습니다. 연구는 표준 화학 요법에 비해 중앙값 전체 생존 기간이 거의 두 배에 가까워진 것을 보였습니다. 면역 세포 강화제인 ANKTIVA는 PD-L1 음성 및 양성 환자 모두에서 효과를 보였으며, 자연살해세포와 기억 T 세포를 활성화했습니다. 체크포인트 억제제와 함께 사용하기 위한 ANKTIVA의 등록을 논의하기 위해 FDA와의 회의가 예정되어 있습니다. 회사는 1억 달러의 비희석 현금 주입을 받아, 방광암 치료를 위한 ANKTIVA 출시를 위해 현금 2억 4천만 달러를 확보했습니다. ImmunityBio는 회의 전화를 통해 등록 계획과 임상 시험 파이프라인에 대해 논의할 계획입니다.
ImmunityBio, Inc. (NASDAQ: IBRX) annonce des résultats positifs concernant la survie globale dans l'essai QUILT 3.055 pour les patients atteints d'un cancer du poumon non à petites cellules qui n'ont pas répondu aux inhibiteurs de points de contrôle. L'étude a révélé un doublement presque de la survie globale médiane par rapport à la chimiothérapie standard. ANKTIVA, un amplificateur de cellules immunitaires, a démontré son efficacité chez les patients négatifs et positifs pour PD-L1, en activant les cellules tueuses naturelles et les cellules T mémoires. Une rencontre avec la FDA est prévue pour discuter de l'enregistrement d'ANKTIVA en combinaison avec les inhibiteurs de points de contrôle. La société a reçu une injection de fonds non dilutive de 100 millions de dollars, portant les disponibilités à 240 millions de dollars pour le lancement d'ANKTIVA dans le cancer de la vessie. ImmunityBio prévoit de discuter des plans d'enregistrement et du pipeline d'essais cliniques lors d'une conférence téléphonique.
ImmunityBio, Inc. (NASDAQ: IBRX) meldet positive Gesamtergebnisse zum Überleben im QUILT 3.055-Studie für Patienten mit nicht-kleinzelligem Lungenkrebs, die nicht auf Checkpoint-Inhibitoren ansprachen. Die Studie zeigte eine nahezu doppelte mittlere Gesamtüberlebenszeit im Vergleich zur Standardchemotherapie. ANKTIVA, ein Verstärker für Immunzellen, zeigte Wirksamkeit bei PD-L1-negativen und -positiven Patienten, indem es natürliche Killerzellen und Gedächtnis-T-Zellen aktivierte. Ein Treffen mit der FDA ist geplant, um die Zulassung von ANKTIVA in Kombination mit Checkpoint-Inhibitoren zu besprechen. Das Unternehmen erhielt eine nicht-verwässernde Barzufuhr von 100 Millionen Dollar, was die Barreserven auf 240 Millionen Dollar für den Start von ANKTIVA bei Blasenkrebs erhöht. ImmunityBio plant, die Registrierungspläne und die klinische Studienpipeline während eines Telefonkonferenz zu besprechen.
Positive
  • Positive overall survival results in the QUILT 3.055 trial for NSCLC patients.
  • ANKTIVA showed effectiveness in activating immune cells regardless of PD-L1 status.
  • Meeting with FDA scheduled to discuss registration for ANKTIVA in NSCLC.
  • Company received $100 million cash infusion for ANKTIVA launch.
  • Conference call planned to address registration plans and clinical trials.
Negative
  • None.

The QUILT 3.055 trial's results are promising, showing a median overall survival for NSCLC patients almost double that of the standard of care. The effectiveness of ANKTIVA in activating natural killer and memory T cells appears to offer a new avenue for patients who have shown resistance to checkpoint inhibitors. These findings could reshape treatment protocols and provide a valuable option for patients with limited alternatives.

The projected 100 million in non-dilutive cash infusion post-ANKTIVA's approval could significantly bolster ImmunityBio's financial position, raising cash-on-hand to approximately 240 million. This development should reassure investors about the company's fiscal strength to launch ANKTIVA in NMIBC and support its clinical trial pipeline. It highlights ImmunityBio's potential for revenue growth and the possibility of expanding ANKTIVA's application to other tumor types.

With lung cancer being a major oncological challenge and NSCLC making up a significant fraction of cases, the successful development and potential FDA approval of ANKTIVA could disrupt the market. The drug's capacity to improve outcomes where previous treatments have failed positions it to capture a considerable market share, not only in lung cancer but potentially other solid tumors, reflecting ImmunityBio's strategic focus on addressing unmet medical needs.
  • QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy
  • Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC
  • Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types
  • Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus checkpoint inhibitors in 2nd- and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy
  • $100 million in non-dilutive cash infusion with ANKTIVA approval brings cash-on-hand to approximately $240 million for launch of ANKTIVA in non-muscle invasive bladder cancer (NMIBC)
  • Company has scheduled a conference call to discuss registration plans for NSCLC, status of ANKTIVA launch readiness for NMIBC, and ANKTIVA as the backbone of our clinical trial pipeline for multiple tumor types

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio’s belief in the unique mechanism of action of ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) and its potential efficacy as a next-generation immunotherapy across multiple solid and liquid tumor types.

In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor. The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival. These positive results were noted regardless of the patient’s PD-L1 status, consistent with the mechanism of action of ANKTIVA in activating and proliferating natural killer cells, and stimulating CD8+ Killer Memory T cells. This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.

A meeting with the FDA has been scheduled for June to discuss the company’s overall survival results in PD-L1 negative and positive patients and registration plans for 2nd-line and 3rd-line NSCLC patients whose cancer did not respond or continue to respond to checkpoint therapy and for whom few alternative therapies are available.

The positive overall survival data of patients enrolled in QUILT 3.055, a basket trial across multiple tumor types, in which checkpoint inhibitors failed, will be discussed, along with the status of launch readiness for ANKTIVA for its recently approved indication in NMIBC on an investor conference call Friday, April 26 at 8 am PDT/11 am EDT.

“The results we noted with the completion of the QUILT 3.055 basket trial across multiple tumor types in patients with late-stage cancers for whom standard of care plus checkpoints failed, validates our hypothesis that orchestration of NK cells with killer T cells and memory T cells could result in meaningful clinical improvements to current standards of care. We hypothesized that activation and proliferation of natural killer cells through IL-15 stimulation could rescue T cells after checkpoint failure, regardless of tumor type or of tumor location. As with non-muscle invasive bladder cancer, we believe that ANKTIVA enhanced the NK and T cell activity critical for targeting and killing cancer cells which have entered the phase of tumor evasion and resistance,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. “QUILT 3.055 was the initial and seminal study of our Cancer Moonshot program launched in January 2016 (see related video here). The findings of a significant extension of overall survival in 2nd- and 3rd-line lung cancer affirms that combination therapy, with the orchestration of the innate and adaptive immune system, could potentially lead to the evolution of immunotherapy beyond T cells for all cancer patients. We are excited that these results continue to demonstrate the broad potential for ANKTIVA across multiple tumor types and its role as the next-generation immunotherapy. We are committed to pursuing additional indications for ANKTIVA in our pipeline with a mission to deliver new hope to patients with serious, advanced cancers where standard therapies have failed.”

The QUILT trials initiated since the launch of the Cancer Moonshot program across multiple tumor types can be found on ImmunityBio.com and are summarized in the figure accompanying this announcement. As can be seen, ANKTIVA (N-803) serves as the backbone to the immunotherapy vaccine across multiple tumor types at late-stage with exploratory evidence of complete remissions. Updates to this figure denoting the QUILT trials at the time of publication in 2021 will be forthcoming.

According to the American Cancer Society, lung cancer is the second most common cancer in the U.S. In 2023, it is estimated that 238,340 new cases of lung cancer will be diagnosed in the U.S. and 127,070 deaths will be attributed to the disease. NSCLC accounts for about 80% to 85% of all lung cancers diagnoses and there are very few successful treatment options for these patients once the cancer spreads beyond the lungs.

The development of checkpoint inhibitors in NSCLC has been revolutionary, doubling the median overall survival in some settings; however, patient response may be short lived, due to late response and/or progression after achieving an initial response. Historical and real-world experience (RWE) data show that the median overall survival rates in these patients range from 7 to 9 months.

In addition, the company will provide information about the status of launch readiness of ANKTIVA for NMIBC. Presentations by the company on ANKTIVA data in NMIBC are scheduled at the upcoming American Urological Association (AUA) conference in San Antonio, Texas from May 3-6, 2024. It is anticipated the first vials of ANKTIVA will be available for shipment the week of May 6, 2024.

Further details regarding ANKTIVA as the backbone of ImmunityBio’s late-stage clinical pipeline across multiple solid and liquid tumor types will be discussed during the conference call, along with commercial launch readiness details, and the corporate financial position to support launch of ANKTIVA for the U.S. market.

Conference call details:

Investors may access the live audio webcast of the call via this weblink. A replay of the webcast will be available at https://ir.immunitybio.com. All participants may join the call by dialing (800) 579-2543 (U.S. and Canada Toll-Free) or (785) 424-1789 and using the access code ANKTIVA.

About ImmunityBio

ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

For more information, please visit: www.immunitybio.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding data and results from clinical trials and potential implications therefrom, commercialization plans and timelines, including product availability and shipments, potential regulatory pathways and approval requests and submissions, FDA meetings, timelines and potential results therefrom, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, information regarding potential benefit to patients, information regarding ongoing pre-clinical studies and clinical trials, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, methods, conference call and webcast timing, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the risks and uncertainties associated with commercial launch execution, success and timing, (ii) risks and uncertainties related to the regulatory submission and review process, (iii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) the timing and funding of the incremental $100 million of non-dilutive financing following ImmunityBio’s receipt of FDA approval of the BLA, (v) ImmunityBio’s ability to retain and hire key personnel, (vi) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (vii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (viii) ImmunityBio’s ability to successfully commercialize its product candidates and uncertainties around regulatory reviews and approvals, (ix) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its product candidates and future approved products, and (x) ImmunityBio’s ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 19, 2024 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Investors

Hemanth Ramaprakash, PhD, MBA

ImmunityBio, Inc.

+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media

Greg Tenor

Salutem

+1 717-919-6794

Gregory.Tenor@Salutemcomms.com

Source: ImmunityBio, Inc.

FAQ

What are the positive results announced by ImmunityBio (IBRX) in the QUILT 3.055 trial for NSCLC patients?

ImmunityBio reported positive overall survival results in the QUILT 3.055 trial for 2nd- and 3rd-line NSCLC patients who did not respond to checkpoint inhibitors. The study showed a nearly double median overall survival compared to standard chemotherapy.

What is the mechanism of action of ANKTIVA as mentioned in the PR by ImmunityBio (IBRX)?

ANKTIVA functions as an immune cell enhancer that activates natural killer cells and memory T cells. It was effective in both PD-L1 negative and positive NSCLC patients, rescuing checkpoint inhibitor failures.

What is the purpose of the meeting scheduled with the FDA by ImmunityBio (IBRX)?

ImmunityBio has a meeting planned with the FDA in June to discuss the registration path for ANKTIVA in combination with checkpoint inhibitors for 2nd- and 3rd-line NSCLC patients.

How much non-dilutive cash infusion did ImmunityBio (IBRX) receive and what is it intended for?

ImmunityBio received a $100 million non-dilutive cash infusion. This funding brings the cash-on-hand to approximately $240 million for the launch of ANKTIVA in non-muscle invasive bladder cancer.

What upcoming event is ImmunityBio (IBRX) planning to address registration plans and clinical trial pipeline?

ImmunityBio has scheduled a conference call to discuss registration plans for NSCLC, the status of ANKTIVA launch readiness for bladder cancer, and ANKTIVA's role in the clinical trial pipeline for multiple tumor types.

ImmunityBio, Inc.

NASDAQ:IBRX

IBRX Rankings

IBRX Latest News

IBRX Stock Data

4.50B
145.27M
79.62%
8.85%
8.09%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO